Is neupogen given as an iv or a subcutaneous injection?

How is Neupogen administered?

Neupogen (filgrastim) is given as a subcutaneous injection under the skin, typically in the abdomen, thigh, or upper arm. It can also be administered intravenously (IV) in hospital settings, such as for chemotherapy patients, but subcutaneous is the primary outpatient route.[1]

When is IV used instead of subcutaneous?

IV infusion is common during chemotherapy cycles in clinical settings, lasting 15-30 minutes or up to 24 hours via continuous pump. Subcutaneous injections are preferred for self-administration at home, with daily doses using prefilled syringes.[1][2]

Dosage forms available

• Prefilled syringes (300 mcg/0.5 mL or 480 mcg/0.8 mL) for subcutaneous use.
  
• Single-use vials for dilution in IV infusions.
  Subcutaneous doses are injected once daily; IV follows similar dosing but requires medical supervision.[1]
  
  

Common patient instructions

Patients rotate injection sites to avoid irritation. No shaking of syringes. Store refrigerated; allow to warm to room temperature before injecting. Self-injection training is provided by healthcare providers.[2]

Differences from biosimilars like Zarxio

Zarxio (filgrastim-sndz), a Neupogen biosimilar, uses the same routes—subcutaneous or IV—with identical dosing. Both reduce infection risk in neutropenia.[3]

[1]: Neupogen Prescribing Information (Amgen)
[2]: FDA Label for Neupogen
[3]: Zarxio Prescribing Information (Sandoz)